Kinarus Therapeutics Initiates KIN001 Phase II KINFAST Clinical Trial in COVID-19 Outpatients

Kinarus Therapeutics Holding AG announced that the first patient has been dosed in the Phase II KINFAST trial, a multicenter placebo-controlled trial evaluating KIN001 in mild or moderate COVID-19 patients in an outpatient setting.